



CoreTherm® - Experience meeting was a success

ProstaLund organized a national Experience Meeting for CoreTherm® users in Stockholm from 31 March to 1 April. The participants' evaluation confirms ProstaLund's own opinion that the meeting was a success.

During Thursday-Friday last week, ProstaLund hosted CoreTherm® - Experience Meeting. About 35 users, urologists, and nurses, participated in a successful event. In addition to the sessions for open exchange of experiences, participants listened to some presentations:

Dr. Fredrik Stenmark, Kalmar, once again presented his results from 570 CoreTherm® treatments on large prostates and sent the following message to his colleagues: "For men with urination problems and large prostates, the low retreatment rate means that CoreTherm® challenges all other methods to be the first choice when choosing a curative treatment."

Dr. Björn Zackrisson, Solna, told us that most of their first 140 CoreTherm® treatments ended with good outcomes. They have also started the use of CoreFlow® - Soft Stent instead of a regular catheter in the period after the treatment and it has so far worked well on a majority of patients.

Dr. Dag Sandblom, Solna/Örebro, explained how clear they are about highlighting the side effects of thermotherapy treatment before patients decide to move forward. From the first more than 200 treatments, he brought with him some patient cases with good treatment results and very satisfied gentlemen who are happy to recommend the treatment to others.

Dr Sonny Schelin, Kalmar, presented a descriptive analysis of how they at the Specialistläkargruppen during the burning pandemic managed to treat 757 patients without having become infected/infected any patient. Most patients have travelled to treatment from regions other than Kalmar, the average age was 73.5 years, about 30% of the patients had comorbidity that most likely caused them to be denied surgery, 40% came for a referral while 60% had applied themselves through the free choice of care, the average size of the prostates was 70 cc, the treatments took an average of 8.5 minutes, 30% used catheter before treatment. He has also on a small scale successfully used CoreFlow® - Soft Stent as a diagnostic tool before treatment to determine whether patients are suitable for treatment or not.

In addition, representatives from ProstaLund presented both CoreFlow® - Soft Stent and the urine flow meter Oruflow and gave an update on the current situation for benign prostate enlargement in Sweden where the queues are getting longer and where fewer and fewer people are getting a cure despite a sharply increased older male population in the last 25 years.



PRESS RELEASE
04 April 2022 15:00:00 CEST

"I left Stockholm on Friday with a very nice feeling. A fantastic meeting in a very positive atmosphere contributed to spreading knowledge and experience between our customers," says CEO Johan Wennerholm.

For further information, please contact:

Johan Wennerholm, CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company's lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:

Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

Attachments

CoreTherm® - Experience meeting was a success